NCT03537742View on ClinicalTrials.gov

Cardiac Allograft Vasculopathy Inhibition with Alirocumab

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

July 28, 2025

Study Completion Date

August 28, 2025

Conditions
Vasculopathy
Interventions
BIOLOGICAL

alirocumab

alirocumab 150mg Subcutaneous

BIOLOGICAL

placebo

placebo to match alirocumab

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Stanford University

OTHER

NCT03537742 - Cardiac Allograft Vasculopathy Inhibition with Alirocumab | Biotech Hunter | Biotech Hunter